Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis

Journal of Clinical Pathology

Volumn 65, Issue 1, 2012, Pages 83-86

  McCulloch, Elaine ^a   Ramage, Gordon ^b   Rajendran, Ranjith ^b   Lappin, David F ^b   Jones, Brian ^c   Warn, Peter ^d   Shrief, Raghdaa ^d   Kirkpatrick, William R ^e   Patterson, Thomas F ^e   Williams, Craig ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; GALACTOMANNAN; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; EXPERIMENTAL MODEL; INVASIVE ASPERGILLOSIS; LABORATORY DIAGNOSIS; LUNG ASPERGILLOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; SENSITIVITY AND SPECIFICITY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DNA, FUNGAL; EARLY DIAGNOSIS; ECHINOCANDINS; IMMUNOENZYME TECHNIQUES; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; MICROBIOLOGICAL TECHNIQUES; MYCOLOGICAL TYPING TECHNIQUES; PREDICTIVE VALUE OF TESTS; RATS; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS; TRIAZOLES;

EID: 84355166570     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2011.090464     Document Type: Article

References (18)

1. Auberger J, Lass-Florl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008;88:508-15.
2. Challier S, Boyer S, Abachin E, et al. Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2004;42:844-6. (Pubitemid 38222678)
3. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006;91:986-9. (Pubitemid 44023159)
4. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173:707-17.
5. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999;12:310-50.
6. McCulloch E, Ramage G, Jones B, et al. Don' throw your blood clots away: use of blood clot may improve sensitivity of PCR diagnosis in invasive aspergillosis. J Clin Pathol 2009;62:539-41.
7. Felton TW, Baxter C, Moore CB, et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010;51:1383-91.
8. Zhao Y, Park S, Warn P, et al. Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol 2010;48:1378-83.
9. White PL, Bretagne S, Klingspor L, et al. European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010;48:1231-40.
10. Hummel M, Spiess B, Cornely OA, et al. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Haematol 2010;85:164-9.
11. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005;40:1762-9. (Pubitemid 40799945)
12. Vallor AC, Kirkpatrick WR, Najvar LK, et al. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob Agents Chemother 2008;52:2593-8. (Pubitemid 351915692)
13. Ahmad S, Khan ZU, Theyyathel AM. Diagnostic value of DNA, (1-3)-beta-D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus. Diagn Microbiol Infect Dis 2007;59:165-71. (Pubitemid 47496092)
14. Morton CO, Loeffler J, De Luca A, et al. Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol 2010;59:408-13.
15. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004;42:5517-22. (Pubitemid 39664330)
16. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002;46:12-23. (Pubitemid 34031596)
17. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69. (Pubitemid 32182037)
18. Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol 2009;16:1844-6.